Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 132,837,664
  • Shares Outstanding, K 1,504,220
  • Annual Sales, $ 28,216 M
  • Annual Income, $ 5,309 M
  • 36-Month Beta 1.62
  • Price/Sales 4.70
  • Price/Cash Flow 13.40
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.92
  • Number of Estimates 8
  • High Estimate 2.02
  • Low Estimate 1.88
  • Prior Year 1.48
  • Growth Rate Est. (year over year) +29.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
77.50 +16.31%
on 11/01/18
92.41 -2.46%
on 10/17/18
+0.96 (+1.08%)
since 10/15/18
3-Month
77.50 +16.31%
on 11/01/18
100.23 -10.07%
on 08/20/18
-7.31 (-7.50%)
since 08/15/18
52-Week
77.50 +16.31%
on 11/01/18
125.86 -28.38%
on 01/26/18
-3.62 (-3.86%)
since 11/15/17

Most Recent Stories

More News
Mission Therapeutics and AbbVie Sign DUBs Collaboration in Alzheimer's and Parkinson's Disease

Mission Therapeutics ("Mission"), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) and AbbVie ("AbbVie")(NYSE: ABBV), a research-based...

ABBV : 90.14 (+2.07%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline - ABBV

NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc. (''AbbVie'' or the ''Company'') (NYSE: ABBV) and certain of its officers....

ABBV : 90.14 (+2.07%)
AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day.

ABBV : 90.14 (+2.07%)
AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today presented for the first time additional results from two replicate...

NBIX : 91.71 (+6.48%)
ABBV : 90.14 (+2.07%)
AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study

AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.

JNJ : 144.50 (+0.17%)
MRK : 74.84 (+1.01%)
LLY : 112.20 (+2.18%)
ABBV : 90.14 (+2.07%)
AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi

AstraZeneca (AZN) to sell U.S. rights of Synagis to Sobi for an upfront consideration of $1.5 billion as it streamlines its portfolio

AZN : 41.40 (unch)
ABBV : 90.14 (+2.07%)
November 20th AbbVie Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against AbbVie Inc. - ABBV

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the important November 20, 2018 lead plaintiff deadline in the shareholder class action lawsuit against AbbVie...

ABBV : 90.14 (+2.07%)
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018

NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV)...

ABBV : 90.14 (+2.07%)
The Zacks Analyst Blog Highlights: Berkshire Hathaway, AbbVie, Booking, HCA and Kimberly-Clark

The Zacks Analyst Blog Highlights: Berkshire Hathaway, AbbVie, Booking, HCA and Kimberly-Clark

KMB : 110.79 (-0.17%)
HCA : 137.74 (-1.51%)
ABBV : 90.14 (+2.07%)
BKNG : 1,888.87 (+0.03%)
AbbVie to Present at the Evercore ISI Conference

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Evercore ISI HealthConX Conference on Tuesday, November 27, 2018. Bill Chase, executive vice president, finance...

ABBV : 90.14 (+2.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ABBV with:

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

2nd Resistance Point 91.00
1st Resistance Point 89.66
Last Price 90.14
1st Support Level 86.71
2nd Support Level 85.10

See More

52-Week High 125.86
Fibonacci 61.8% 107.39
Fibonacci 50% 101.68
Fibonacci 38.2% 95.97
Last Price 90.14
52-Week Low 77.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar